

Recombinant Human TNFRSF17/BCMA Protein (His & Fc Tag)(Active)

Catalog No. PKSH031503

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	BCM;BCMA;CD269;TNFRSF13A
Species	Human
Expression Host	HEK293 Cells
Sequence	Met 1-Ala 54
Accession	NP_001183.2
Calculated Molecular Weight	34 kDa
Observed molecular weight	40 kDa
Tag	C-His & Fc
Bioactivity	Measured by its binding ability in a functional ELISA. Immobilized recombinant human BAFF at 1 µg/ml (100 µl/well) can bind human TNFRSF17. The EC50 of human TNFRSF17 is 0.07 µg/ml.

Properties

Purity	> 85 % as determined by reducing SDS-PAGE.
Storage	Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4
Reconstitution	Please refer to the printed manual for detailed information.

Data



Background

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBBAFF), and to lead to NF-

For Research Use Only

kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

For Research Use Only

Toll-free: 1-888-852-8623

Web: www.elabscience.com

Tel: 1-832-243-6086

Email: techsupport@elabscience.com

Fax: 1-832-243-6017